Nxera Pharma's QUVIVIQ Receives Approval In Taiwan For The Treatment Of Insomnia

Nxera Pharma's partner Holling Bio-Pharma received TFDA approval to market QUVIVIQ 25 mg and 50 mg in Taiwan for adult insomnia patients. The approval expands access for the sleep-disorder treatment and is a modestly positive commercial/regulatory development for Nxera. The news is likely to have limited near-term market impact, but it improves the product's regional rollout potential.

Analysis

Nxera Pharma's partner Holling Bio-Pharma received TFDA approval to market QUVIVIQ 25 mg and 50 mg in Taiwan for adult insomnia patients. The approval expands access for the sleep-disorder treatment and is a modestly positive commercial/regulatory development for Nxera. The news is likely to have limited near-term market impact, but it improves the product's regional rollout potential.